欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (4): 446-450.doi: 10.12092/j.issn.1009-2501.2019.04.013

• 药物治疗学 • 上一篇    下一篇

阿立哌唑联合草酸艾司西酞普兰对重度抑郁患者多巴胺、5-羟色胺和皮质醇的影响研究

陈连洲,李松华,蒲 犇   

  1. 宁波市精神病院老年精神科,宁波 315000,浙江
  • 收稿日期:2019-01-31 修回日期:2019-03-23 出版日期:2019-04-26 发布日期:2019-05-01
  • 作者简介:陈连洲,男,本科,副主任医师,研究方向:老年精神病学。 Tel:13736186880 E-mail:hwl181105@163.com
  • 基金资助:

    浙江省医药卫生科技计划项目(2019315497)

Effects of aripiprazole combined with escitalopram oxalate on DA, 5-HT and cortisol in patients with severe depression

CHEN Lianzhou, LI Songhua, PU Ben   

  1. Geriatric Psychiatry Department, Ningbo Psychiatric Hospital, Ningbo 315000, Zhejiang, China
  • Received:2019-01-31 Revised:2019-03-23 Online:2019-04-26 Published:2019-05-01

摘要:

目的:探讨阿立哌唑联合草酸艾司西酞普兰对重度抑郁患者多巴胺(DA)、5-羟色胺(5-HT)和皮质醇的影响。方法:将94例重度抑郁症患者分为观察组和对照组。对照组采用草酸艾司西酞普兰治疗。观察组采用阿立哌唑联合草酸艾司西酞普兰治疗。采用汉密尔顿焦虑量表(HAMD-17)评估患者的抑郁状态。检测两组患者治疗前后DA、5-HT、皮质醇的水平。采用健康状况问卷(SF-36)评估患者的生存质量,包括生理功能、躯体疼痛、生理职能、精神健康、情感职能、生命活力、社会功能、总体健康。观察两组患者治疗过程中不良反应的发生情况。结果:观察组的有效率比对照组高,差异有统计学意义(P<0.05);两组治疗后的皮质醇、HAMD-17评分显著降低,DA、5-HT显著升高,差异有统计学意义(P<0.05);观察组治疗后的皮质醇、HAMD-17评分低于对照组,DA、5-HT高于对照组,差异有统计学意义(P<0.05);两组治疗后的生理功能、躯体疼痛、生理职能、精神健康、情感职能、生命活力、社会功能、总体健康显著升高,差异有统计学意义(P<0.05);观察组治疗后的生理功能、躯体疼痛、生理职能、精神健康、情感职能、生命活力、社会功能、总体健康高于对照组,差异有统计学意义(P<0.05)。两组的不良反应发生率差异无统计学意义(P>0.05)。结论:阿立哌唑可进一步调节重度抑郁患者DA、5-HT和皮质醇的水平,提高临床疗效,改善生存质量。

关键词: 阿立哌唑, 草酸艾司西酞普兰, 重度抑郁, 多巴胺, 5-羟色胺, 皮质醇

Abstract:

AIM: To investigate the effects of aripiprazole combined with escitalopram oxalate on DA, 5-HT and cortisol in patients with severe depression.  METHODS: 94 patients with severe depression were divided into observation group and control group. The control group was treated with escitalopram oxalate. The observation group was treated with aripiprazole combined with escitalopram oxalate. Hamilton Anxiety Scale (HAMD-17) was used to assess the depressive state of patients. The levels of dopamine (DA), 5-hydroxytryptamine (5-HT) and cortisol were measured before and after treatment in both groups. Health status questionnaire (SF-36) was used to assess patients' quality of life, including physiological function, physical pain, physiological function, mental health, emotional function, life vitality, social function and overall health. The occurrences of adverse reactions in the course of treatment in two groups were observed. RESULTS:The effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, cortisol and HAMD-17 scores in both groups decreased significantly as compared with before treatment, while DA and 5-HT increased significantly (P<0.05). After treatment, cortisol and HAMD-17 scores in the observation group were lower than those in the control group, while DA and 5-HT scores in the observation group were higher than those in the control group (P<0.05). After treatment, the physiological function, physical pain, physiological function, mental health, emotional function, vitality, social function and overall health of the two groups increased significantly (P<0.05). After treatment, the physiological function, physical pain, physiological function, mental health, emotional function, vitality, social function and overall health of the observation group were higher than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups. CONCLUSION:Aripiprazole can further regulate the levels of DA, 5-HT and cortisol in patients with severe depression, and improve the clinical efficacy and quality of life.

Key words: aripiprazole, escitalopram oxalate, severe depression, dopamine, 5-HT, cortisol

中图分类号: